Loading…

No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors

Farnesoid X receptor (FXR) has been recently reported to enhance chemoresistance through bile acid-independent mechanisms. Thus, FXR transfection plus activation with GW4064 resulted in reduced sensitivity to cisplatin-induced toxicity. This is interesting because primary tumors of the liver, an org...

Full description

Saved in:
Bibliographic Details
Published in:Molecular pharmaceutics 2012-06, Vol.9 (6), p.1693-1704
Main Authors: Martinez-Becerra, P, Vaquero, J, Romero, M. R, Lozano, E, Anadon, C, Macias, R. I. R, Serrano, M. A, Grañé-Boladeras, N, Muñoz-Bellvis, L, Alvarez, L, Sangro, B, Pastor-Anglada, M, Marin, J. J. G
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a348t-3e20cf46bdca14d3b8036c9bda18d73c569e2aa882c8bceb5c381e8b2152a0ad3
cites cdi_FETCH-LOGICAL-a348t-3e20cf46bdca14d3b8036c9bda18d73c569e2aa882c8bceb5c381e8b2152a0ad3
container_end_page 1704
container_issue 6
container_start_page 1693
container_title Molecular pharmaceutics
container_volume 9
creator Martinez-Becerra, P
Vaquero, J
Romero, M. R
Lozano, E
Anadon, C
Macias, R. I. R
Serrano, M. A
Grañé-Boladeras, N
Muñoz-Bellvis, L
Alvarez, L
Sangro, B
Pastor-Anglada, M
Marin, J. J. G
description Farnesoid X receptor (FXR) has been recently reported to enhance chemoresistance through bile acid-independent mechanisms. Thus, FXR transfection plus activation with GW4064 resulted in reduced sensitivity to cisplatin-induced toxicity. This is interesting because primary tumors of the liver, an organ where FXR is expressed, exhibit marked refractoriness to pharmacological treatment. Here we have determined whether FXR is upregulated in hepatocellular carcinoma (HCC), cholangiocarcinoma (CGC) and hepatoblastoma (HPB) and whether this is related with the expression of genes involved in mechanisms of chemoresistance. Using RT-QPCR and Taqman low density arrays we have analyzed biopsies from healthy livers or surgically removed tumors from naive patients and cell lines derived from HCC (SK-HEP-1, Alexander and Huh7), CGC (TFK1) and HPB (HepG2), before and after exposure to cisplatin at IC50 for 72 h. In liver tumors FXR expression was not enhanced but significantly decreased (healthy liver > HCC > HPB ≈ CGC). Except for CGC, this was not accompanied by changes in the proportions of FXR isoforms. Changes in 36 genes involved in drug uptake/efflux and metabolism, expression/function of molecular targets, and survival/apoptosis balance were found. Changes affecting SLC22A1, CYP2A1 and BIRC5 were shared by HCC, CGC and HPB. Similarity in gene expression profiles between cell lines and parent tumors was found. Pharmacological challenge with cisplatin induced changes that increased this resemblance. This was not dependent upon FXR expression. Thus, although FXR may play a role in inducing chemoresistance under certain circumstances, its upregulation does not seem to be involved in the multidrug resistance phenotype characteristic of HCC, CGC and HPB.
doi_str_mv 10.1021/mp300028a
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1687662299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1687662299</sourcerecordid><originalsourceid>FETCH-LOGICAL-a348t-3e20cf46bdca14d3b8036c9bda18d73c569e2aa882c8bceb5c381e8b2152a0ad3</originalsourceid><addsrcrecordid>eNptkE1PwkAQhjdGI4ge_ANmLyZ6qO5HW7ZHQwBJUAnBxFuz3R2kpN2tuy3Kv7cE5ORpJpNn3sw8CF1T8kAJo49lxQkhTMgT1KVRyAPBE3Z67EXYQRfer1skjBg_Rx3GIhbSiHfR9tXigXUOClnn1uAM6m8Ag-sV4OFP5cD73dgu8ehjjqXReAwGPJ6YjS02oHFu8EtT1Ll2zSeeg899LY0CPFuBsfW2gt3uzOWldFs8zTfg8KIprfOX6GwpCw9Xh9pD76PhYvAcTN_Gk8HTNJA8FHXAgRG1DONMK0lDzTNBeKySTEsqdJ-rKE6ASSkEUyJTkEWKCwoiYzRikkjNe-hun1s5-9WAr9My9wqKQhqwjU9pLPpxzFiStOj9HlXOeu9gmVb7w1NK0p3p9Gi6ZW8OsU1Wgj6Sf2pb4HYPSOXTtW2cab_8J-gXceuGcA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1687662299</pqid></control><display><type>article</type><title>No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Martinez-Becerra, P ; Vaquero, J ; Romero, M. R ; Lozano, E ; Anadon, C ; Macias, R. I. R ; Serrano, M. A ; Grañé-Boladeras, N ; Muñoz-Bellvis, L ; Alvarez, L ; Sangro, B ; Pastor-Anglada, M ; Marin, J. J. G</creator><creatorcontrib>Martinez-Becerra, P ; Vaquero, J ; Romero, M. R ; Lozano, E ; Anadon, C ; Macias, R. I. R ; Serrano, M. A ; Grañé-Boladeras, N ; Muñoz-Bellvis, L ; Alvarez, L ; Sangro, B ; Pastor-Anglada, M ; Marin, J. J. G</creatorcontrib><description>Farnesoid X receptor (FXR) has been recently reported to enhance chemoresistance through bile acid-independent mechanisms. Thus, FXR transfection plus activation with GW4064 resulted in reduced sensitivity to cisplatin-induced toxicity. This is interesting because primary tumors of the liver, an organ where FXR is expressed, exhibit marked refractoriness to pharmacological treatment. Here we have determined whether FXR is upregulated in hepatocellular carcinoma (HCC), cholangiocarcinoma (CGC) and hepatoblastoma (HPB) and whether this is related with the expression of genes involved in mechanisms of chemoresistance. Using RT-QPCR and Taqman low density arrays we have analyzed biopsies from healthy livers or surgically removed tumors from naive patients and cell lines derived from HCC (SK-HEP-1, Alexander and Huh7), CGC (TFK1) and HPB (HepG2), before and after exposure to cisplatin at IC50 for 72 h. In liver tumors FXR expression was not enhanced but significantly decreased (healthy liver &gt; HCC &gt; HPB ≈ CGC). Except for CGC, this was not accompanied by changes in the proportions of FXR isoforms. Changes in 36 genes involved in drug uptake/efflux and metabolism, expression/function of molecular targets, and survival/apoptosis balance were found. Changes affecting SLC22A1, CYP2A1 and BIRC5 were shared by HCC, CGC and HPB. Similarity in gene expression profiles between cell lines and parent tumors was found. Pharmacological challenge with cisplatin induced changes that increased this resemblance. This was not dependent upon FXR expression. Thus, although FXR may play a role in inducing chemoresistance under certain circumstances, its upregulation does not seem to be involved in the multidrug resistance phenotype characteristic of HCC, CGC and HPB.</description><identifier>ISSN: 1543-8384</identifier><identifier>EISSN: 1543-8392</identifier><identifier>DOI: 10.1021/mp300028a</identifier><identifier>PMID: 22524153</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Apoptosis - drug effects ; Apoptosis - genetics ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - genetics ; Carcinoma, Hepatocellular - metabolism ; Cell Line, Tumor ; Cholangiocarcinoma - drug therapy ; Cholangiocarcinoma - genetics ; Cholangiocarcinoma - metabolism ; Cisplatin - pharmacology ; Cisplatin - therapeutic use ; Drug Resistance, Multiple - genetics ; Drug Resistance, Neoplasm - genetics ; Hep G2 Cells ; Hepatoblastoma - drug therapy ; Hepatoblastoma - genetics ; Hepatoblastoma - metabolism ; Humans ; In Vitro Techniques ; Liver - metabolism ; Liver - pathology ; Liver Neoplasms - drug therapy ; Liver Neoplasms - genetics ; Liver Neoplasms - metabolism ; Receptors, Cytoplasmic and Nuclear - genetics ; Receptors, Cytoplasmic and Nuclear - metabolism</subject><ispartof>Molecular pharmaceutics, 2012-06, Vol.9 (6), p.1693-1704</ispartof><rights>Copyright © 2012 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a348t-3e20cf46bdca14d3b8036c9bda18d73c569e2aa882c8bceb5c381e8b2152a0ad3</citedby><cites>FETCH-LOGICAL-a348t-3e20cf46bdca14d3b8036c9bda18d73c569e2aa882c8bceb5c381e8b2152a0ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22524153$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martinez-Becerra, P</creatorcontrib><creatorcontrib>Vaquero, J</creatorcontrib><creatorcontrib>Romero, M. R</creatorcontrib><creatorcontrib>Lozano, E</creatorcontrib><creatorcontrib>Anadon, C</creatorcontrib><creatorcontrib>Macias, R. I. R</creatorcontrib><creatorcontrib>Serrano, M. A</creatorcontrib><creatorcontrib>Grañé-Boladeras, N</creatorcontrib><creatorcontrib>Muñoz-Bellvis, L</creatorcontrib><creatorcontrib>Alvarez, L</creatorcontrib><creatorcontrib>Sangro, B</creatorcontrib><creatorcontrib>Pastor-Anglada, M</creatorcontrib><creatorcontrib>Marin, J. J. G</creatorcontrib><title>No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors</title><title>Molecular pharmaceutics</title><addtitle>Mol. Pharmaceutics</addtitle><description>Farnesoid X receptor (FXR) has been recently reported to enhance chemoresistance through bile acid-independent mechanisms. Thus, FXR transfection plus activation with GW4064 resulted in reduced sensitivity to cisplatin-induced toxicity. This is interesting because primary tumors of the liver, an organ where FXR is expressed, exhibit marked refractoriness to pharmacological treatment. Here we have determined whether FXR is upregulated in hepatocellular carcinoma (HCC), cholangiocarcinoma (CGC) and hepatoblastoma (HPB) and whether this is related with the expression of genes involved in mechanisms of chemoresistance. Using RT-QPCR and Taqman low density arrays we have analyzed biopsies from healthy livers or surgically removed tumors from naive patients and cell lines derived from HCC (SK-HEP-1, Alexander and Huh7), CGC (TFK1) and HPB (HepG2), before and after exposure to cisplatin at IC50 for 72 h. In liver tumors FXR expression was not enhanced but significantly decreased (healthy liver &gt; HCC &gt; HPB ≈ CGC). Except for CGC, this was not accompanied by changes in the proportions of FXR isoforms. Changes in 36 genes involved in drug uptake/efflux and metabolism, expression/function of molecular targets, and survival/apoptosis balance were found. Changes affecting SLC22A1, CYP2A1 and BIRC5 were shared by HCC, CGC and HPB. Similarity in gene expression profiles between cell lines and parent tumors was found. Pharmacological challenge with cisplatin induced changes that increased this resemblance. This was not dependent upon FXR expression. Thus, although FXR may play a role in inducing chemoresistance under certain circumstances, its upregulation does not seem to be involved in the multidrug resistance phenotype characteristic of HCC, CGC and HPB.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - genetics</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - genetics</subject><subject>Carcinoma, Hepatocellular - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Cholangiocarcinoma - drug therapy</subject><subject>Cholangiocarcinoma - genetics</subject><subject>Cholangiocarcinoma - metabolism</subject><subject>Cisplatin - pharmacology</subject><subject>Cisplatin - therapeutic use</subject><subject>Drug Resistance, Multiple - genetics</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Hep G2 Cells</subject><subject>Hepatoblastoma - drug therapy</subject><subject>Hepatoblastoma - genetics</subject><subject>Hepatoblastoma - metabolism</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - genetics</subject><subject>Liver Neoplasms - metabolism</subject><subject>Receptors, Cytoplasmic and Nuclear - genetics</subject><subject>Receptors, Cytoplasmic and Nuclear - metabolism</subject><issn>1543-8384</issn><issn>1543-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNptkE1PwkAQhjdGI4ge_ANmLyZ6qO5HW7ZHQwBJUAnBxFuz3R2kpN2tuy3Kv7cE5ORpJpNn3sw8CF1T8kAJo49lxQkhTMgT1KVRyAPBE3Z67EXYQRfer1skjBg_Rx3GIhbSiHfR9tXigXUOClnn1uAM6m8Ag-sV4OFP5cD73dgu8ehjjqXReAwGPJ6YjS02oHFu8EtT1Ll2zSeeg899LY0CPFuBsfW2gt3uzOWldFs8zTfg8KIprfOX6GwpCw9Xh9pD76PhYvAcTN_Gk8HTNJA8FHXAgRG1DONMK0lDzTNBeKySTEsqdJ-rKE6ASSkEUyJTkEWKCwoiYzRikkjNe-hun1s5-9WAr9My9wqKQhqwjU9pLPpxzFiStOj9HlXOeu9gmVb7w1NK0p3p9Gi6ZW8OsU1Wgj6Sf2pb4HYPSOXTtW2cab_8J-gXceuGcA</recordid><startdate>20120604</startdate><enddate>20120604</enddate><creator>Martinez-Becerra, P</creator><creator>Vaquero, J</creator><creator>Romero, M. R</creator><creator>Lozano, E</creator><creator>Anadon, C</creator><creator>Macias, R. I. R</creator><creator>Serrano, M. A</creator><creator>Grañé-Boladeras, N</creator><creator>Muñoz-Bellvis, L</creator><creator>Alvarez, L</creator><creator>Sangro, B</creator><creator>Pastor-Anglada, M</creator><creator>Marin, J. J. G</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20120604</creationdate><title>No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors</title><author>Martinez-Becerra, P ; Vaquero, J ; Romero, M. R ; Lozano, E ; Anadon, C ; Macias, R. I. R ; Serrano, M. A ; Grañé-Boladeras, N ; Muñoz-Bellvis, L ; Alvarez, L ; Sangro, B ; Pastor-Anglada, M ; Marin, J. J. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a348t-3e20cf46bdca14d3b8036c9bda18d73c569e2aa882c8bceb5c381e8b2152a0ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - genetics</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - genetics</topic><topic>Carcinoma, Hepatocellular - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Cholangiocarcinoma - drug therapy</topic><topic>Cholangiocarcinoma - genetics</topic><topic>Cholangiocarcinoma - metabolism</topic><topic>Cisplatin - pharmacology</topic><topic>Cisplatin - therapeutic use</topic><topic>Drug Resistance, Multiple - genetics</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Hep G2 Cells</topic><topic>Hepatoblastoma - drug therapy</topic><topic>Hepatoblastoma - genetics</topic><topic>Hepatoblastoma - metabolism</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - genetics</topic><topic>Liver Neoplasms - metabolism</topic><topic>Receptors, Cytoplasmic and Nuclear - genetics</topic><topic>Receptors, Cytoplasmic and Nuclear - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martinez-Becerra, P</creatorcontrib><creatorcontrib>Vaquero, J</creatorcontrib><creatorcontrib>Romero, M. R</creatorcontrib><creatorcontrib>Lozano, E</creatorcontrib><creatorcontrib>Anadon, C</creatorcontrib><creatorcontrib>Macias, R. I. R</creatorcontrib><creatorcontrib>Serrano, M. A</creatorcontrib><creatorcontrib>Grañé-Boladeras, N</creatorcontrib><creatorcontrib>Muñoz-Bellvis, L</creatorcontrib><creatorcontrib>Alvarez, L</creatorcontrib><creatorcontrib>Sangro, B</creatorcontrib><creatorcontrib>Pastor-Anglada, M</creatorcontrib><creatorcontrib>Marin, J. J. G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Molecular pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martinez-Becerra, P</au><au>Vaquero, J</au><au>Romero, M. R</au><au>Lozano, E</au><au>Anadon, C</au><au>Macias, R. I. R</au><au>Serrano, M. A</au><au>Grañé-Boladeras, N</au><au>Muñoz-Bellvis, L</au><au>Alvarez, L</au><au>Sangro, B</au><au>Pastor-Anglada, M</au><au>Marin, J. J. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors</atitle><jtitle>Molecular pharmaceutics</jtitle><addtitle>Mol. Pharmaceutics</addtitle><date>2012-06-04</date><risdate>2012</risdate><volume>9</volume><issue>6</issue><spage>1693</spage><epage>1704</epage><pages>1693-1704</pages><issn>1543-8384</issn><eissn>1543-8392</eissn><abstract>Farnesoid X receptor (FXR) has been recently reported to enhance chemoresistance through bile acid-independent mechanisms. Thus, FXR transfection plus activation with GW4064 resulted in reduced sensitivity to cisplatin-induced toxicity. This is interesting because primary tumors of the liver, an organ where FXR is expressed, exhibit marked refractoriness to pharmacological treatment. Here we have determined whether FXR is upregulated in hepatocellular carcinoma (HCC), cholangiocarcinoma (CGC) and hepatoblastoma (HPB) and whether this is related with the expression of genes involved in mechanisms of chemoresistance. Using RT-QPCR and Taqman low density arrays we have analyzed biopsies from healthy livers or surgically removed tumors from naive patients and cell lines derived from HCC (SK-HEP-1, Alexander and Huh7), CGC (TFK1) and HPB (HepG2), before and after exposure to cisplatin at IC50 for 72 h. In liver tumors FXR expression was not enhanced but significantly decreased (healthy liver &gt; HCC &gt; HPB ≈ CGC). Except for CGC, this was not accompanied by changes in the proportions of FXR isoforms. Changes in 36 genes involved in drug uptake/efflux and metabolism, expression/function of molecular targets, and survival/apoptosis balance were found. Changes affecting SLC22A1, CYP2A1 and BIRC5 were shared by HCC, CGC and HPB. Similarity in gene expression profiles between cell lines and parent tumors was found. Pharmacological challenge with cisplatin induced changes that increased this resemblance. This was not dependent upon FXR expression. Thus, although FXR may play a role in inducing chemoresistance under certain circumstances, its upregulation does not seem to be involved in the multidrug resistance phenotype characteristic of HCC, CGC and HPB.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>22524153</pmid><doi>10.1021/mp300028a</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1543-8384
ispartof Molecular pharmaceutics, 2012-06, Vol.9 (6), p.1693-1704
issn 1543-8384
1543-8392
language eng
recordid cdi_proquest_miscellaneous_1687662299
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Apoptosis - drug effects
Apoptosis - genetics
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - genetics
Carcinoma, Hepatocellular - metabolism
Cell Line, Tumor
Cholangiocarcinoma - drug therapy
Cholangiocarcinoma - genetics
Cholangiocarcinoma - metabolism
Cisplatin - pharmacology
Cisplatin - therapeutic use
Drug Resistance, Multiple - genetics
Drug Resistance, Neoplasm - genetics
Hep G2 Cells
Hepatoblastoma - drug therapy
Hepatoblastoma - genetics
Hepatoblastoma - metabolism
Humans
In Vitro Techniques
Liver - metabolism
Liver - pathology
Liver Neoplasms - drug therapy
Liver Neoplasms - genetics
Liver Neoplasms - metabolism
Receptors, Cytoplasmic and Nuclear - genetics
Receptors, Cytoplasmic and Nuclear - metabolism
title No Correlation between the Expression of FXR and Genes Involved in Multidrug Resistance Phenotype of Primary Liver Tumors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T15%3A38%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20Correlation%20between%20the%20Expression%20of%20FXR%20and%20Genes%20Involved%20in%20Multidrug%20Resistance%20Phenotype%20of%20Primary%20Liver%20Tumors&rft.jtitle=Molecular%20pharmaceutics&rft.au=Martinez-Becerra,%20P&rft.date=2012-06-04&rft.volume=9&rft.issue=6&rft.spage=1693&rft.epage=1704&rft.pages=1693-1704&rft.issn=1543-8384&rft.eissn=1543-8392&rft_id=info:doi/10.1021/mp300028a&rft_dat=%3Cproquest_cross%3E1687662299%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a348t-3e20cf46bdca14d3b8036c9bda18d73c569e2aa882c8bceb5c381e8b2152a0ad3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1687662299&rft_id=info:pmid/22524153&rfr_iscdi=true